Literature DB >> 34127730

Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes.

Andang Miatmoko1, Ira Nurjannah2, Nuril Fadilatul Nehru2, Noorma Rosita2, Esti Hendradi2, Retno Sari2, Juni Ekowati2.   

Abstract

This study aimed to analyze the interaction of primaquine (PQ), chloroquine (CQ), and liposomes to support the design of optimal liposomal delivery for hepatic stage malaria infectious disease. The liposomes were composed of hydrogenated soybean phosphatidylcholine, cholesterol, and distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy[polyethyleneglycol]-2000), prepared by thin film method, then evaluated for physicochemical and spectrospic characteristics. The calcein release was further evaluated to determine the effect of drug co-loading on liposomal membrane integrity. The results showed that loading PQ and CQ into liposomes produced changes in the infrared spectra of the diester phosphate and carbonyl ester located in the polar part of the phospholipid, in addition to the alkyl group (CH2) in the nonpolar portion. Moreover, the thermogram revealed the loss of the endothermic peak of liposomes dually loaded with PQ and CQ at 186.6 °C, which is identical to that of the phospholipid. However, no crystallinity changes were detected through powder X-ray diffraction analysis. Moreover, PQ, with either single or dual loading, produced the higher calcein release profiles from the liposomes than that of CQ. The dual loading of PQ and CQ tends to interact with the polar head group of the phosphatidylcholine bilayer membrane resulted in an increase in water permeability of the liposomes.

Entities:  

Year:  2021        PMID: 34127730     DOI: 10.1038/s41598-021-91866-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  35 in total

Review 1.  Current therapies and future possibilities for drug development against liver-stage malaria.

Authors:  Rene Raphemot; Dora Posfai; Emily R Derbyshire
Journal:  J Clin Invest       Date:  2016-06-01       Impact factor: 14.808

Review 2.  Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Authors:  Carol Hopkins Sibley; Ric N Price
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-20       Impact factor: 4.077

Review 3.  Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.

Authors:  Sean R Marcsisin; Gregory Reichard; Brandon S Pybus
Journal:  Pharmacol Ther       Date:  2016-03-22       Impact factor: 12.310

4.  Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.

Authors:  David R Hill; J Kevin Baird; Monica E Parise; Linda S Lewis; Edward T Ryan; Alan J Magill
Journal:  Am J Trop Med Hyg       Date:  2006-09       Impact factor: 2.345

Review 5.  Primaquine in vivax malaria: an update and review on management issues.

Authors:  Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Malar J       Date:  2011-12-12       Impact factor: 2.979

Review 6.  Strategies to reverse drug resistance in malaria.

Authors:  Timothy J Egan; Catherine H Kaschula
Journal:  Curr Opin Infect Dis       Date:  2007-12       Impact factor: 4.915

7.  The reality of using primaquine.

Authors:  Kathy L Burgoine; Germana Bancone; François Nosten
Journal:  Malar J       Date:  2010-12-27       Impact factor: 2.979

8.  Pharmacokinetic interactions between primaquine and chloroquine.

Authors:  Sasithon Pukrittayakamee; Joel Tarning; Podjanee Jittamala; Prakaykaew Charunwatthana; Saranath Lawpoolsri; Sue J Lee; Warunee Hanpithakpong; Borimas Hanboonkunupakarn; Nicholas P J Day; Elizabeth A Ashley; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 9.  Management of relapsing Plasmodium vivax malaria.

Authors:  Cindy S Chu; Nicholas J White
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-31       Impact factor: 5.091

10.  Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.

Authors:  Pius S Fasinu; Babu L Tekwani; Bharathi Avula; Narayan D Chaurasiya; N P Dhammika Nanayakkara; Yan-Hong Wang; Ikhlas A Khan; Larry A Walker
Journal:  Malar J       Date:  2016-09-13       Impact factor: 2.979

View more
  2 in total

1.  Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics.

Authors:  Adonis Sfera; Sabine Hazan; Jonathan J Anton; Dan O Sfera; Christina V Andronescu; Sarvin Sasannia; Leah Rahman; Zisis Kozlakidis
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

2.  Improving the anti-ageing activity of coenzyme Q10 through protransfersome-loaded emulgel.

Authors:  Qurrota Ayunin; Andang Miatmoko; Widji Soeratri; Tristiana Erawati; Joni Susanto; Djoko Legowo
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.